Find Clinical Drug Pipeline Developments & Deals for Doxcercalciferol

Doxcercalciferol
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Doxcercalciferol

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

15 API Suppliers, 10 USDMF, 2 EU WC, 4 NDC API, 8 Listed Suppliers

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

35 FDF Dossiers, 33 FDA Orange Book, 2 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 10MCG/5ML (2MCG/ML), INJECTABLE;INJECTION - 4MCG/2ML (2MCG/ML), CAPSULE;ORAL - 0.5MCG, CAPSULE;ORAL - 1MCG, CAPSULE;ORAL - 2.5MCG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 7 DKSH, 2 Nanjing Well Pharmaceutical, 6 Kirsch Pharma, 4 ACG Worldwide, 4 Actylis, 3 BASF, 1 Finar, 1 Gangwal Chemicals, 3 Lonza Capsugel, 1 Pluviaendo, 1 Qualicaps, 2 Roquette, 3 Seppic, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

15 Parenteral, 8 Empty Capsules, 8 Topical, 7 Solubilizers, 7 Thickeners and Stabilizers, 6 Coating Systems & Additives, 5 Film Formers & Plasticizers, 5 Fillers, Diluents & Binders, 3 Surfactant & Foaming Agents, 3 Coloring Agents, 2 Emulsifying Agents, 1 Taste Masking

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

3 US Medicaid Prescriptions

MARKET PLACE

6 APIs

6 APIs

PATENTS & EXCLUSIVITIES

3 US Exclusivities

3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Doxcercalciferol

Therapeutic Area : Nephrology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 09, 2016

Lead Product(s) : Doxcercalciferol

Therapeutic Area : Nephrology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow